Cefiderocol: the Trojan horse has arrived but will Troy fall?

Affiliations

¹ Department of Pharmacy, University of Maryland School of Pharmacy, Baltimore, MD 21201, USA. Electronic address: eheil@rx.umaryland.edu.
² Department of Pediatrics, Johns Hopkins Hospital, Baltimore, MD, USA.

Comment

Emily L Heil et al. Lancet Infect Dis. 2021 Feb.

. 2021 Feb;21(2):153-155.

doi: 10.1016/S1473-3099(20)30828-8. Epub 2020 Oct 12.

¹ Department of Pharmacy, University of Maryland School of Pharmacy, Baltimore, MD 21201, USA. Electronic address: eheil@rx.umaryland.edu.
² Department of Pediatrics, Johns Hopkins Hospital, Baltimore, MD, USA.

No abstract available

Comment on

Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R, Lodise TP, Naas T, Niki Y, Paterson DL, Portsmouth S, Torre-Cisneros J, Toyoizumi K, Wunderink RG, Nagata TD. Bassetti M, et al. Lancet Infect Dis. 2021 Feb;21(2):226-240. doi: 10.1016/S1473-3099(20)30796-9. Epub 2020 Oct 12. Lancet Infect Dis. 2021. PMID: 33058795 Clinical Trial.
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.
Wunderink RG, Matsunaga Y, Ariyasu M, Clevenbergh P, Echols R, Kaye KS, Kollef M, Menon A, Pogue JM, Shorr AF, Timsit JF, Zeitlinger M, Nagata TD. Wunderink RG, et al. Lancet Infect Dis. 2021 Feb;21(2):213-225. doi: 10.1016/S1473-3099(20)30731-3. Epub 2020 Oct 12. Lancet Infect Dis. 2021. PMID: 33058798 Clinical Trial.